Phosplatin Therapeutics Inc.

Tyler D Ames

Matthew Price

Wayne Douglas Luke

Use of (pyrophosphato)platinum(II) or platinum(IV) complexes ('phosphaplatins'), especially 1,2-cyclohexanediamine(pyrophosphato) platinum(II), as immunogenic cell death (ICD) inducing agents and their combination with immune checkpoint protein inhibitors for treatment of cancers, and the mechanistic rationale for the methods thereof, are disclosed.

Phosphaplatin compounds as immuno-modulatory agents and therapeutic uses thereof

Pharmaceutical compositions of phosphaplatin compounds, in particular buffered stable liquid formulations of pyrodach-2 ready for use in the treatment of various cancers, and methods of preparation are disclosed.

Phosphaplatin liquid formulations

Use of (pyrophosphato)platinum(II) or (pyrophosphato)platinum(IV) complexes ('phosphaplatin compounds'), especially (R,R)-1,2-cyclohexanediamine-(dihydrogen pyrophosphato)platinum(II) (or 'PT-112'), as therapeutic agents for treatment of bone and blood cancers, or cancers that metastasize to bones, and methods thereof, are disclosed.

Growing community of inventors

Long Island City, NY, United States of America

Tyler D Ames